Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

3-week Study of Asenapine, Olanzapine and Placebo for Treatment of Bipolar Mania (P07009)

This study has been completed.
Sponsor:
Collaborator:
Pfizer
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT00159796
First received: September 8, 2005
Last updated: September 21, 2015
Last verified: September 2015